Comparison of these activated Ki67+CD38+ CD4 T cells revealed landscape differences independent of vaccination or time point in patients with MS treated with aCD20 versus healthy controls (Fig. 2b). The gene discussed is MKI67; the disease is myeloid sarcoma.